Key Highlights

  • Ginkgo Bioworks closed at $14.98, giving the company a Market Value of about $1 billion.
  • No new company release was found for the day; the move extended momentum from a Sept. 15 Eli Lilly partnership.
  • The shares have roughly doubled since the Lilly deal was announced.
  • Life-science tools makers broadly rallied the same day even as big drugmakers lagged.

Ginkgo Bioworks shares surged again on Monday, extending a run that began with its AI drug-discovery Partnership with Eli Lilly, though no new company announcement was found for the day.

Momentum Keeps Building

Ginkgo Bioworks (NYSE:DNA) surged on Monday, Oct. 5, closing at $14.98 and landing among the biggest gainers on the Russell 2000. The move gave the synthetic-biology company a market value of about $1 billion.

No new company release dated Oct. 5 was found. Instead, the rally was tied to continued momentum from Ginkgo's AI drug-discovery partnership with Eli Lilly (NYSE:LLY), announced on Sept. 15. The shares have roughly doubled since that deal.

The Lilly Connection

The partnership centers on Lilly TuneLab, Lilly's AI drug-discovery effort. For Ginkgo, a tie-up with one of the world's most valuable drugmakers puts a high-profile partner behind its push to use its biological data and lab automation in AI-driven research.

Partnerships with big pharmaceutical companies can matter more for smaller biotech platforms than the dollar figures alone suggest. They can attract new customers and signal that larger players see value in a company's tools.

Ginkgo Bioworks runs a platform that helps customers engineer cells, using automated labs and large biological datasets. Its customers range from drug developers to agriculture and industrial companies. Its share price has been volatile.

That Volatility helps explain why a single high-profile partnership can drive such a large move. For a company of Ginkgo's size, news involving a partner as large as Lilly can trigger a rapid shift in sentiment, and momentum traders can amplify it. A stock that has roughly doubled in a few weeks can also swing sharply in either direction as traders lock in gains or pile in.

Biotech and Tools in the Spotlight

Monday was mixed for health care. Big drugmakers struggled: Merck (NYSE:MRK) was the worst stock in the Dow and Bristol-Myers Squibb (NYSE:BMY) fell after a Leerink Partners downgrade. But life-science tools makers rallied, including Charles River Laboratories (NYSE:CRL), Illumina (NASDAQ:ILMN), Thermo Fisher Scientific (NYSE:TMO) and Danaher (NYSE:DHR).

Eli Lilly itself edged higher with no company-specific news. Several smaller biotechs with specific news also rose, including Vaxcyte (NASDAQ:PCVX) on Vaccine data and Alector (NASDAQ:ALEC) on a licensing deal with Genentech.

The Market Backdrop

The broader market helped. The Russell 2000 rose 14.24 points to 2,847.14. The Nasdaq Composite climbed 286.45 points to a record 27,477.31, the S&P 500 rose 51.23 points to 7,773.95, just shy of its summer record, and the Dow added 90.94 points to 51,267.90. AI-linked stocks led, with Nvidia (NASDAQ:NVDA) closing at a record and a market value of about $5.7 trillion. Ginkgo, which pitches AI-driven research, rallied on the same day, though no source directly linked its move to the megacap gains.

Friday's weak September jobs report, showing payrolls up just 29,000, cut bets on another Fed hike in October. But the 10-year Treasury Yield climbed to its highest level since 2002, and the ISM services survey showed prices paid at their highest since July 2022.

What to Watch Next

With no new company announcement behind Monday's move, investors will watch for updates on the Lilly partnership and on any new customer deals that build on it. Any formal disclosure from the company would also help clarify what is driving the shares. The company's next Quarterly Report will show whether the rally is backed by changes in its Revenue and spending.

On the macro calendar, the Fed releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. For Ginkgo, any formal disclosure tied to the Lilly partnership would do more to explain the rally than anything from the Fed.